About the API
Selexipag, which belongs to a class of drugs termed anti-hypertensive agents, is used for the treatment of a lung disease, called pulmonary arterial hypertension (PAH). In PAH, high blood pressure in the lungs may cause shortness of breath and physical limitations, and can lead to death or the need for lung transplantation.
Administered orally, selexipag acts by relaxing the arteries connecting the heart to the lungs. In clinical trials, selexipag was shown to be effective in reducing hospitalization for PAH and reducing the risks of disease progression.
Developed by Nippon Shinyaku and Actelion Pharmaceuticals, Selexipag was approved by the FDA in 2015 under the trade name Uptravi.
It is produced through multi-step chemical synthesis.